摘要
目的研究巴曲酶对糖尿病大鼠肾脏的保护作用。方法将Wistar大鼠分为正常组(C)、糖尿病组(M)、治疗1组(T1)、治疗2组(T2)和治疗3组(T3)。除正常组外,其余四组用链尿佐菌素诱导大鼠糖尿病模型,T1、T2和T3组分别于大鼠出现高血糖、尿微量白蛋白及肾脏早期病理改变时给予巴曲酶治疗。实验共进行8周,实验过程中观察大鼠体质量、饮食、饮水量、精神及尿量变化。每2周检测血糖1次,于实验第2周、6周、7周和8周分别用代谢笼收集各组大鼠尿液,测定24h尿白蛋白排泄量。8周末时,在10%水合氯醛麻醉状态下,腹主动脉取抗凝血和血清,用于测定糖化血红蛋白(HbA1c)、血糖(BS)、血肌酐(Scr)、尿素氮(BUN)等指标,并计算血清肌酐清除率(Ccr)。留取单侧肾脏称重,计算肾脏肥大指数(肾重/体质量)。结果4周末发现糖尿病组大鼠肾脏基膜增生系膜区扩大,出现早期肾脏病理改变。2、6、7、8周糖尿病组大鼠24h尿白蛋白排泄量明显高于健康对照组(P<0.01),给予巴曲酶治疗后,白蛋白排泄较糖尿病组明显降低(P<0.01或0.05)。8周末发现糖尿病大鼠Scr、BUN、HbA1c、肾脏指数均较健康对照组明显升高(P<0.01或0.05).Ccr较健康对照组明显降低(P<0.01),症状均有所缓解(P<0.01或0.05)。结论巴曲酶可能具有改善糖尿病大鼠肾小球滤过率,降低糖化血红蛋白水平,有利于控制血糖,阻断糖尿病大鼠肾脏病变发展的作用。
Objective To assess the effects of batroxobin（DF-521） on the kideney of diabetic rats and explore its mechanism. Methods Wistar rats were divided randomly into five groups：control group（C） ,diabetic group （M） ,treatment 1 group（T1）,treatment 2 group（T2） and treatment 3 group（T3）. The M,T1 ,T2 and T3 groups were made diabetes mellitus by intraperitoneal injection of streptoxotocin（STZ） and the T1 ,T2 and T3 group were treated with batroxobin when the daibetic rats developed hyperglycemia, conspicuous 24 hours urinary albumin （mALB） and kidney nonage pathology change. In the experiment, the weight, food and drink, spirit and urine volume were Observed and the blood sugar（BS） was detected for every two weeks. The urine with metabolic cage in the second, sixth,seventh and eighth week was collected respectively. At the end of the eighth week, the rats were anesthetized with 10 % chloral hydrate and the blood in abdominal aorta was drew to detect BS, glycosylated hemoglobin （HbA1 c）, blood urea nitrogen （ BUN ）, serum ereatinine （Scr） . creatinine clearance （ Ccr ） were also calculated. The kidney index（kidney weight to body weight,KW/BW） and mALB were detected. Results At the end of the fourth week, the kidney of diabetic rats appeared increased basement membrane and amplified mesangial region. Compared with control group, mALB of the diabetic rats in 2nd, 6th, 7th and 8th week were increased significanty（ P 〈 0.01 ）. The levels of three treatment groups were deeresed compared with those of M group（P 〈 0.05 or 0.01）. Scr,BUN HbAlc, kidney index of diabetic rats were increased（ P 〈 0.05 or 0.01 ）, Ccr level was decreased significantly（ P 〈 0.01 ）. The above mentioned symptom was relieved with batroxobin. Conclusion Batroxobin can block the development of renal lesions of diabetic rats by improving the glomerular filtration rate, decreasing the level of HbAle and inhibiting BS.
出处
《中国基层医药》
CAS
2007年第9期1459-1461,共3页
Chinese Journal of Primary Medicine and Pharmacy
关键词
巴曲酶
糖尿病肾病
大鼠
Batroxobin
Diabetic nephropathy
Rats
